The UKPDS and its global impact

Diabetic Medicine

Volumn 25, Issue SUPPL. 2, 2008, Pages 57-62

  Genuth, S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness of treatment; Diabetic complications; Glycemic control; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; BUDGET; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; ECONOMIC ASPECT; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL EDUCATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; QUALITY OF LIFE; REVIEW; UNITED KINGDOM; UNITED STATES; WEIGHT GAIN;

BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS;

EID: 47649117733     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02504.x     Document Type: Review

References (54)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
2. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865.
3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1992 329 : 977 986.
4. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). Diabetologia 1991 34 : 877 890.
5. DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995 75 : 894 903.
6. DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Eng J Med 2005 353 : 2643 2653.
7. Johnsson S. Retinopathy and nephropathy in diabetes mellitus: comparison of the effects of two forms of treatment. Diabetes 1960 9 : 1 8.
8. Genuth SM. The case of blood glucose control. Adv Intern Med 1995 40 : 573 623.
9. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991 230 : 101 108.
10. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Eng J Med 1993 329 : 304 309.
11. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996 124 (1 pt 2 104 109.
12. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes 1993 42 : 1555 1558.
13. Nathan DM. Do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care 1995 18 : 251 257.
14. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 28 : 103 117.
15. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1998 21 : 2180 2184.
16. Leslie RD. United Kingdom Prospective Diabetes Study (UKPDS): what now or so what? Diabetes Metab Res Rev 1999 15 : 65 71.
17. Baldeweg SE, Yudkin JS. Implications of the United Kingdom Prospective Diabetes Study. Prim Care 1999 26 : 809 827.
18. Laakso M. Benefits of strict glucose and blood pressure control in Type 2 diabetes. Lessons from the UK Prospective Diabetes Study. Circulation 1999 99 : 461 462.
19. Mehnert H. Diabetologische Realitäten und Wünsche. UKPDS nach einem Jahr. Dtsch med Wschr 1999 124 : 1021.
20. Pontiroli AE, Folli F. Is it worth treating diabetes? Lessons from the UKPDS. Acta Diabetol 1998 335 : 170 171.
21. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998 352 : 832 833.
22. Budenholzer B. Glycaemia and vascular effects of Type 2 diabetes. BMJ 2001 322 : 1245.
23. McCormack J, Greenhalgh T. Seeing what you want to see in randomized controlled trials: versions and perversions of UKPDS data. BMJ 2000 320 : 1720 1723.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998 317 : 703 713.
25. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR et al. Meta-Analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004 141 : 421 431.
26. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M et al. Glycemic control and macrovascular disease in Types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006 152 : 27 38.
27. UK Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Diabetes 1995 44 : 1249 1258.
28. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin patients with Type 2 diabetes mellitus. JAMA 1999 281 : 2005 2012.
29. Inzucchi SE. Oral antihypergiycemic therapy for Type 2 diabetes. JAMA 2002 287 : 360 372.
30. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006 29 : 1963 1972.
31. Perquin M, Michel GH, de Beaufort C, Keipes M, Wirion R, Haas N. Changes in diabetes prevalence and treatment in the last ten years in Luxembourg. A lesson from the United Kingdom prospective diabetes study? Diabetes Metab 2005 31 : 499 502.
32. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes Care 2008 31 : 81 86.
33. Huang X, Reichberg S, Green M, Koski E, Kaufman H, Kaufman F et al. Factors affecting the seasonal pattern in hemoglobin A1c values: analyses of data from a large reference laboratory database. Presented at the American Diabetes Association Annual Meeting, Washington DC, USA, June 9-13, 2006.
34. Department of Health. Quality and Outcomes Framework. NHS Information Centre for Health and Social Care, September 2007. UK : Department of Health. http://www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/QOF/indes. htm
35. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S, for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabetic Med 2005 22 : 1420 1426.
36. Goldfracht M, Levin D, Peled O, Poraz I, Stern E, Weiss D et al. Diabetes in the community - ten years of chronic disease management program. Community Division, Clalit Health Services, Tel Aviv Israel, 2006.
37. Elis A, Rosenmann L, Chodick G, Heymann AD, Kokia E, Shalev V. The association between glycemic, lipids and blood pressure control among Israeli diabetic patients. Q J Med 2008 101 : 275 280.
38. Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia - a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002 19 : 978 85.
39. Skrha J for the Committee of the Czech Diabetes Society. Diabetes mellitus 2002 in the Czech Republic - Epidemiological Study. Diabetol Metab Endokrinol 2005 8 : 5 12.
40. Orozco-Beltrán D, Gil-Guillen VF, Quirce F, Navarro-Perez J, Pineda M, Gomez-de-la-Cámara A et al. Collaborative diabetes study investigators. Control of diabetes and cardiovascular risk factors in patients with Type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract 2007 61 : 909 915.
41. Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M et al. The status of diabetes control and antidiabetic drug therapy in Japan - A cross-sectional survey of 17 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006 73 : 198 204.
42. Gerstl EM, Rabl W, Rosenbauer J, Gröbe H, Hofer SE, Krause U et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with Type-1 diabetes mellitus: combined longitudinal analysis including 27 035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr 2008 167 : 447 453.
43. Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjö rnsdóttir S, for the Steering Committee of the Swedish National Diabetes Register. Antihyperglycaemic treatment of Type 2 diabetes: results from a national diabetes register. Diabetes Metab 2007 33 : 269 276.
44. LeRoith D. Our evolving understanding of getting to goal using insulin in Type 2 diabetes. Endocrinol Metab Clin North Am 2007 36 (Suppl. 2 9 19.
45. GfK Market Measures, 2007. http://www.gfk.com/gfkmm/
46. Philis-Tsimikas A, Walker C, Rivard L, Talavera G, Reimann JO, Salmon M et al. Improvement in diabetes care of underinsured patients enrolled in Project Dulce. A community-based, culturally appropriate, nurse care management and peer education diabetes care model. Diabetes Care 2004 27 : 110 115.
47. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025; prevalence, numerical estimates, and projections. Diabetes Care 1998 21 : 1414 1431.
48. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, on behalf of the UK Prospective Diabetes Study (UKPDS). Cost-utility analyses of intensive blood glucose and tight blood pressure control in Type 2 diabetes (UKPDS 72). Diabetologia 2005 48 : 868 877.
49. Clark P, Gray A, Adler A, Stevens R, Raikou M, Cull C et al. on behalf of the UKPDS Group. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51). Diabetologia 2001 44 : 298 304.
50. Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in Type 2 diabetes in England: cost analysis (UKPDS 63). BMJ 2002 325 : 860.
51. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 412.
52. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al. on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 321 : 412 419.
53. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006 49 : 1761 1769.
54. Stevens RJ, Kothari V, Adler AI, Stratton IM, on behalf of the UK Prospective Diabetes Study Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clin Sci 2001 101 : 671 679.